NDC 0069-2025 Comirnaty
Covid-19 Vaccine, Mrna Injection, Suspension Intramuscular

Product Information

What is NDC 0069-2025?

The NDC code 0069-2025 is assigned by the FDA to the product Comirnaty which is a vaccine label product labeled by Pfizer Laboratories Div Pfizer Inc. The generic name of Comirnaty is covid-19 vaccine, mrna. The product's dosage form is injection, suspension and is administered via intramuscular form. The product is distributed in 2 packages with assigned NDC codes 0069-2025-10 10 vial, glass in 1 carton / 2.25 ml in 1 vial, glass (0069-2025-01), 0069-2025-25 25 vial, glass in 1 carton / 2.25 ml in 1 vial, glass (0069-2025-01). This page includes all the important details about this product, including active and inactive ingredients, pharmagologic classes, product uses and characteristics, UNII information, RxNorm crosswalk and the complete product label.

NDC Product Code0069-2025
Proprietary Name What is the Proprietary Name?
The proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
Comirnaty
Non-Proprietary Name What is the Non-Proprietary Name?
The non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
Covid-19 Vaccine, Mrna
Product Type What kind of product is this?
Indicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
Vaccine
Dosage FormInjection, Suspension - A liquid preparation, suitable for injection, which consists of solid particles dispersed throughout a liquid phase in which the particles are not soluble. It can also consist of an oil phase dispersed throughout an aqueous phase, or vice-versa.
Administration Route(s) What are the Administration Route(s)?
The translation of the route code submitted by the firm, indicating route of administration.
  • Intramuscular - Administration within a muscle.
Product Labeler Information What is the Labeler Name?
Name of Company corresponding to the labeler code segment of the Product NDC.
Pfizer Laboratories Div Pfizer Inc
Labeler Code0069
FDA Application Number What is the FDA Application Number?
This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
BLA125742
Marketing Category What is the Marketing Category?
Product types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
BLA - A product marketed under an approved Biologic License Application.
Start Marketing Date What is the Start Marketing Date?
This is the date that the labeler indicates was the start of its marketing of the drug product.
05-18-2022
Listing Expiration Date What is the Listing Expiration Date?
This is the date when the listing record will expire if not updated or certified by the product labeler.
12-31-2023
Exclude Flag What is the NDC Exclude Flag?
This field indicates whether the product has been removed/excluded from the NDC Directory for failure to respond to FDA"s requests for correction to deficient or non-compliant submissions ("Y"), or because the listing certification is expired ("E"), or because the listing data was inactivated by FDA ("I"). Values = "Y", "N", "E", or "I".
N
NDC Code Structure

What are the uses for Comirnaty?


Product Packages

NDC Code 0069-2025-10

Package Description: 10 VIAL, GLASS in 1 CARTON / 2.25 mL in 1 VIAL, GLASS (0069-2025-01)

NDC Code 0069-2025-25

Package Description: 25 VIAL, GLASS in 1 CARTON / 2.25 mL in 1 VIAL, GLASS (0069-2025-01)

Product Details

What are Comirnaty Active Ingredients?

An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.

Comirnaty Active Ingredients UNII Codes

NDC to RxNorm Crosswalk

What is RxNorm? RxNorm is a normalized naming system for generic and branded drugs that assigns unique concept identifier(s) known as RxCUIs to NDC products.The NDC to RxNorm Crosswalk for this produdct indicates multiple concept unique identifiers (RXCUIs) are associated with this product:
  • RxCUI: 2468235 - SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 30 MCG/0.3 ML Injectable Suspension, 12y+
  • RxCUI: 2468235 - SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension
  • RxCUI: 2593847 - COMIRNATY 30 MCG/0.3 ML Injectable Suspension
  • RxCUI: 2593847 - SARS-CoV-2 (COVID-19) vaccine, mRNA-BNT162b2 0.1 MG/ML Injectable Suspension [Comirnaty]
  • RxCUI: 2593847 - Comirnaty 30 MCG/0.3 ML Injectable Suspension

Comirnaty Inactive Ingredients UNII Codes

The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product.

* Please review the disclaimer below.

Comirnaty Product Label

FDA filings in the form of structured product labels are documents that include all published material associated whith this product. Product label information includes data like indications and usage generic names, contraindications, active ingredients, strength dosage, routes of administration, appearance, usage, warnings, inactive ingredients, etc.

Product Label Table of Contents



1 Indications And Usage



COMIRNATY is a vaccine indicated for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 16 years of age and older.


2 Dosage And Administration



For intramuscular injection only.


2.1 Preparation For Administration



The storage, preparation, and administration information in this Prescribing Information apply to COMIRNATY for individuals 16 years of age and older supplied in multiple dose vials with gray caps and labels with gray borders, which MUST NOT be diluted prior to use.

COMIRNATY Multiple Dose Vial with Gray Cap and Label with a Gray Border
Age RangeDilution InformationDoses Per VialDose Volume
16 years and olderDo not dilute prior to use60.3 mL

DO NOT DILUTE

  • COMIRNATY multiple dose vial with a gray cap and a label with a gray border contains a volume of 2.25 mL, supplied as a frozen suspension that does not contain preservative. Each vial must be thawed prior to administration. DO NOT DILUTE prior to use.
  • Vials may be thawed in the refrigerator [2°C to 8°C (35°F to 46°F)] or at room temperature [up to 25°C (77°F)] [see How Supplied/Storage and Handling (16)].
  • Refer to thawing instructions in the panels below.
  • One vial contains 6 doses of 0.3 mL.
  • Preparation Instructions
    COMIRNATY Vial with Gray Cap and Label with Gray Border –
    Vial Verification

    • Verify that the vial of COMIRNATY has a gray plastic cap and a label with a gray border.
    Gray plastic cap and label with gray border.
    COMIRNATY Vial with Gray Cap and Label with Gray Border –
    Thawing Prior to Use
    • Thaw vial(s) of COMIRNATY before use either by:
      • Allowing vial(s) to thaw in the refrigerator [2°C to 8°C (35°F to 46°F)]. A carton of 10 vials may take up to 6 hours to thaw, and thawed vials can be stored in the refrigerator for up to 10 weeks.
      • Allowing vial(s) to sit at room temperature [up to 25°C (77°F)] for 30 minutes.
      • Vials may be stored at room temperature [up to 25°C (77°F)] for up to 12 hours prior to use.
    • Before use, mix by inverting vaccine vial gently 10 times.
    • Do not shake.
    • Prior to mixing, the thawed vaccine may contain white to off-white opaque amorphous particles.
    • After mixing, the vaccine should appear as a white to off-white suspension with no visible particles.
    • Do not use if liquid is discolored or if particles are observed after mixing.
    Gently × 10
    COMIRNATY Vial with Gray Cap and Label with Gray Border –
    Preparation of Individual 0.3 mL Doses
    • Withdraw 0.3 mL of COMIRNATY preferentially using low dead-volume syringes and/or needles.
    • Each dose must contain 0.3 mL of vaccine.
    • If the amount of vaccine remaining in a single vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
    • Administer immediately.
    Withdraw 0.3 mL dose of vaccine.
    • Record the date and time of first vial puncture on the COMIRNATY vial label.
    • Store between 2°C to 25°C (35°F to 77°F).
    • Discard any unused vaccine 12 hours after first puncture.
    Record the date and time of first puncture.
    Use within 12 hours after first puncture.

    Vials of COMIRNATY with gray caps and labels with gray borders contain 6 doses of 0.3 mL of vaccine. Low dead-volume syringes and/or needles can be used to extract 6 doses from a single vial. If standard syringes and needles are used, there may not be sufficient volume to extract 6 doses from a single vial. Irrespective of the type of syringe and needle,

    • each dose must contain 0.3 mL of vaccine.
    • if the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.
    • do not pool excess vaccine from multiple vials.

2.2 Administration Information



Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. The vaccine will be a white to off-white suspension. Do not administer if vaccine is discolored or contains particulate matter.

Administer a single 0.3 mL dose of COMIRNATY intramuscularly.


2.3 Vaccination Schedule



COMIRNATY is administered intramuscularly as a series of 2 doses (0.3 mL each) 3 weeks apart.

There are no data available on the interchangeability of COMIRNATY with COVID-19 vaccines from other manufacturers to complete the vaccination series. Individuals who have received 1 dose of COMIRNATY should receive a second dose of COMIRNATY to complete the vaccination series.


3 Dosage Forms And Strengths



COMIRNATY is a suspension for injection. Each dose of COMIRNATY supplied in vials with gray caps and labels with gray borders is 0.3 mL.


4 Contraindications



Do not administer COMIRNATY to individuals with known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the COMIRNATY [see Description (11)].


5.1 Management Of Acute Allergic Reactions



Appropriate medical treatment used to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of COMIRNATY.


5.2 Myocarditis And Pericarditis



Postmarketing data demonstrate increased risks of myocarditis and pericarditis, particularly within 7 days following the second dose. The observed risk is higher among males under 40 years of age than among females and older males. The observed risk is highest in males 12 through 17 years of age. Although some cases required intensive care support, available data from short-term follow-up suggest that most individuals have had resolution of symptoms with conservative management. Information is not yet available about potential long-term sequelae. The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/myocarditis.html).


5.3 Syncope



Syncope (fainting) may occur in association with administration of injectable vaccines, including COMIRNATY. Procedures should be in place to avoid injury from fainting.


5.4 Altered Immunocompetence



Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the COMIRNATY.


5.5 Limitation Of Effectiveness



COMIRNATY may not protect all vaccine recipients.


6 Adverse Reactions



In clinical studies, the most commonly reported (≥10%) adverse reactions in participants 16 through 55 years of age following any dose were pain at the injection site (88.6%), fatigue (70.1%), headache (64.9%), muscle pain (45.5%), chills (41.5%), joint pain (27.5%), fever (17.8%), and injection site swelling (10.6%).

In clinical studies, the most commonly reported (≥10%) adverse reactions in participants 56 years of age and older following any dose were pain at the injection site (78.2%), fatigue (56.9%), headache, (45.9%), muscle pain (32.5%), chills (24.8%), joint pain (21.5%), injection site swelling (11.8%), fever (11.5%), and injection site redness (10.4%).


6.1 Clinical Trials Experience



Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a vaccine cannot be directly compared to rates in the clinical trials of another vaccine and may not reflect the rates observed in practice.

The safety of COMIRNATY was evaluated in participants 16 years of age and older in 2 clinical studies conducted in Germany (Study 1), United States, Argentina, Brazil, Turkey, South Africa, and Germany (Study 2). Study BNT162-01 (Study 1) was a Phase 1/2, 2-part, dose-escalation trial that enrolled 60 participants, 18 through 55 years of age and 36 participants, 56 through 85 years of age. Study C4591001 (Study 2) is a Phase 1/2/3 multicenter, multinational, randomized, saline placebo-controlled, double-blinded (Phase 2/3), dose-finding, vaccine candidate-selection and efficacy study that has enrolled approximately 44,047 participants (22,026 COMIRNATY; 22,021 placebo) 16 years of age or older (including 378 and 376 participants 16 through 17 years of age in the vaccine and placebo groups, respectively). Upon issuance of the Emergency Use Authorization (December 11, 2020) for COMIRNATY, participants were unblinded to offer placebo participants COMIRNATY. Participants were unblinded in a phased manner over a period of months to offer placebo participants COMIRNATY. Study 2 also included 200 participants with confirmed stable human immunodeficiency virus (HIV) infection; HIV-positive participants are included in safety population disposition but are summarized separately in safety analyses. Confirmed stable HIV infection was defined as documented viral load <50 copies/mL and CD4 count >200 cells/mm3 within 6 months before enrollment, and on stable antiretroviral therapy for at least 6 months.

At the time of the analysis of the ongoing Study 2 with a data cut-off of March 13, 2021, there were 25,651 (58.2%) participants (13,031 COMIRNATY and 12,620 placebo) 16 years of age and older followed for ≥4 months after the second dose.

Participants 16 years and older in the reactogenicity subset were monitored for solicited local and systemic reactions and use of antipyretic medication after each vaccination in an electronic diary. Participants are being monitored for unsolicited adverse events, including serious adverse events, throughout the study [from Dose 1 through 1 month (all unsolicited adverse events) or 6 months (serious adverse events) after the last vaccination].

Demographic characteristics in Study 2 were generally similar with regard to age, gender, race, and ethnicity among participants who received COMIRNATY and those who received placebo. Overall, among the total participants who received either COMIRNATY or placebo, 50.9% were male, 49.1% were female, 79.3% were 16 through 64 years of age, 20.7% were 65 years of age and older, 82.0% were White, 9.6% were Black or African American, 25.9% were Hispanic/Latino, 4.3% were Asian, and 1.0% were American Indian or Alaska Native.


Other



Local and Systemic Adverse Reactions Solicited in the Study 2

Table 1 and Table 2 present the frequency and severity of reported solicited local and systemic reactions, respectively, within 7 days following each dose of COMIRNATY and placebo in the subset of participants 16 through 55 years of age included in the safety population who were monitored for reactogenicity with an electronic diary.

Table 3 and Table 4 present the frequency and severity of reported solicited local and systemic reactions, respectively, within 7 days of each dose of COMIRNATY and placebo for participants 56 years of age and older.

In participants 16 through 55 years of age after receiving Dose 2, the mean duration of pain at the injection site was 2.5 days (range 1 to 70 days), for redness 2.2 days (range 1 to 9 days), and for swelling 2.1 days (range 1 to 8 days) for participants in the COMIRNATY group. In participants 56 years of age and older after receiving Dose 2, the mean duration of pain at the injection site was 2.4 days (range 1 to 36 days), for redness 3.0 days (range 1 to 34 days), and for swelling 2.6 days (range 1 to 34 days) for participants in the COMIRNATY group.

Table 1: Study 2 – Frequency and Percentages of Participants with Solicited Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 16 Through 55 Years of Age – Reactogenicity Subset of the Safety Population

Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

COMIRNATY
Dose 1
N

N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The N for each reaction was the same, therefore, this information was included in the column header.

=2899
n

n = Number of participants with the specified reaction.

(%)
Placebo
Dose 1
N=2908
n (%)
COMIRNATY
Dose 2
N=2682
n (%)
Placebo
Dose 2
N=2684
n (%)
Notes: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.
No Grade 4 solicited local reactions were reported in participants 16 through 55 years of age.
Redness

Mild: >2.0 to ≤5.0 cm; Moderate: >5.0 to ≤10.0 cm; Severe: >10.0 cm.

  Any (>2.0 cm)156 (5.4)28 (1.0)151 (5.6)18 (0.7)
    Mild113 (3.9)19 (0.7)90 (3.4)12 (0.4)
    Moderate36 (1.2)6 (0.2)50 (1.9)6 (0.2)
    Severe7 (0.2)3 (0.1)11 (0.4)0
Swelling
  Any (>2.0 cm)184 (6.3)16 (0.6)183 (6.8)5 (0.2)
    Mild124 (4.3)6 (0.2)110 (4.1)3 (0.1)
    Moderate54 (1.9)8 (0.3)66 (2.5)2 (0.1)
    Severe6 (0.2)2 (0.1)7 (0.3)0
Pain at the injection site

Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

  Any2426 (83.7)414 (14.2)2101 (78.3)312 (11.6)
    Mild1464 (50.5)391 (13.4)1274 (47.5)284 (10.6)
    Moderate923 (31.8)20 (0.7)788 (29.4)28 (1.0)
    Severe39 (1.3)3 (0.1)39 (1.5)0
Table 2: Study 2 – Frequency and Percentages of Participants with Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 16 Through 55 Years of Age – Reactogenicity Subset of the Safety Population

Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

COMIRNATY
Dose 1
N

N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The N for each reaction or use of antipyretic or pain medication was the same, therefore, this information was included in the column header.

=2899
n

n = Number of participants with the specified reaction.

(%)
Placebo
Dose 1
N=2908
n (%)
COMIRNATY
Dose 2
N=2682
n (%)
Placebo
Dose 2
N=2684
n (%)
Notes: Reactions and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.
No Grade 4 solicited systemic reactions were reported in participants 16 through 55 years of age.
Fever
  ≥38.0°C119 (4.1)25 (0.9)440 (16.4)11 (0.4)
  ≥38.0°C to 38.4°C86 (3.0)16 (0.6)254 (9.5)5 (0.2)
  >38.4°C to 38.9°C25 (0.9)5 (0.2)146 (5.4)4 (0.1)
  >38.9°C to 40.0°C8 (0.3)4 (0.1)39 (1.5)2 (0.1)
  >40.0°C001 (0.0)0
Fatigue

Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity.

  Any1431 (49.4)960 (33.0)1649 (61.5)614 (22.9)
    Mild760 (26.2)570 (19.6)558 (20.8)317 (11.8)
    Moderate630 (21.7)372 (12.8)949 (35.4)283 (10.5)
    Severe41 (1.4)18 (0.6)142 (5.3)14 (0.5)
Headache
  Any1262 (43.5)975 (33.5)1448 (54.0)652 (24.3)
    Mild785 (27.1)633 (21.8)699 (26.1)404 (15.1)
    Moderate444 (15.3)318 (10.9)658 (24.5)230 (8.6)
    Severe33 (1.1)24 (0.8)91 (3.4)18 (0.7)
Chills
  Any479 (16.5)199 (6.8)1015 (37.8)114 (4.2)
    Mild338 (11.7)148 (5.1)477 (17.8)89 (3.3)
    Moderate126 (4.3)49 (1.7)469 (17.5)23 (0.9)
    Severe15 (0.5)2 (0.1)69 (2.6)2 (0.1)
Vomiting

Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration.

  Any34 (1.2)36 (1.2)58 (2.2)30 (1.1)
    Mild29 (1.0)30 (1.0)42 (1.6)20 (0.7)
    Moderate5 (0.2)5 (0.2)12 (0.4)10 (0.4)
    Severe01 (0.0)4 (0.1)0
Diarrhea

Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours.

  Any309 (10.7)323 (11.1)269 (10.0)205 (7.6)
    Mild251 (8.7)264 (9.1)219 (8.2)169 (6.3)
    Moderate55 (1.9)58 (2.0)44 (1.6)35 (1.3)
    Severe3 (0.1)1 (0.0)6 (0.2)1 (0.0)
New or worsened muscle pain
  Any664 (22.9)329 (11.3)1055 (39.3)237 (8.8)
    Mild353 (12.2)231 (7.9)441 (16.4)150 (5.6)
    Moderate296 (10.2)96 (3.3)552 (20.6)84 (3.1)
    Severe15 (0.5)2 (0.1)62 (2.3)3 (0.1)
New or worsened joint pain
  Any342 (11.8)168 (5.8)638 (23.8)147 (5.5)
    Mild200 (6.9)112 (3.9)291 (10.9)82 (3.1)
    Moderate137 (4.7)55 (1.9)320 (11.9)61 (2.3)
    Severe5 (0.2)1 (0.0)27 (1.0)4 (0.1)
Use of antipyretic or pain medication

Severity was not collected for use of antipyretic or pain medication.

805 (27.8)398 (13.7)1213 (45.2)320 (11.9)
Table 3: Study 2 – Frequency and Percentages of Participants with Solicited Local Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 56 Years of Age and Older – Reactogenicity Subset of the Safety Population

Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

COMIRNATY
Dose 1
N

N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. The N for each reaction was the same, therefore, the information was included in the column header.

=2008
n

n = Number of participants with the specified reaction.

(%)
Placebo
Dose 1
N=1989
n (%)
COMIRNATY
Dose 2
N=1860
n (%)
Placebo
Dose 2
N=1833
n (%)
Notes: Reactions were collected in the electronic diary (e-diary) from Day 1 to Day 7 after vaccination.
No Grade 4 solicited local reactions were reported in participants 56 years of age and older.
Redness

Mild: >2.0 to ≤5.0 cm; Moderate: >5.0 to ≤10.0 cm; Severe: >10.0 cm.

  Any (>2.0 cm)106 (5.3)20 (1.0)133 (7.2)14 (0.8)
    Mild71 (3.5)13 (0.7)65 (3.5)10 (0.5)
    Moderate30 (1.5)5 (0.3)58 (3.1)3 (0.2)
    Severe5 (0.2)2 (0.1)10 (0.5)1 (0.1)
Swelling
  Any (>2.0 cm)141 (7.0)23 (1.2)145 (7.8)13 (0.7)
    Mild87 (4.3)11 (0.6)80 (4.3)5 (0.3)
    Moderate52 (2.6)12 (0.6)61 (3.3)7 (0.4)
    Severe2 (0.1)04 (0.2)1 (0.1)
Pain at the injection site

Mild: does not interfere with activity; Moderate: interferes with activity; Severe: prevents daily activity.

  Any (>2.0 cm)1408 (70.1)185 (9.3)1230 (66.1)143 (7.8)
    Mild1108 (55.2)177 (8.9)873 (46.9)138 (7.5)
    Moderate296 (14.7)8 (0.4)347 (18.7)5 (0.3)
    Severe4 (0.2)010 (0.5)0
Table 4: Study 2 – Frequency and Percentages of Participants with Solicited Systemic Reactions, by Maximum Severity, Within 7 Days After Each Dose – Participants 56 Years of Age and Older – Reactogenicity Subset of the Safety Population

Randomized participants in the safety analysis population who received at least 1 dose of the study intervention. Participants with chronic, stable HIV infection were excluded.

COMIRNATY
Dose 1
N

N = Number of participants reporting at least 1 yes or no response for the specified reaction after the specified dose. N for each reaction or use of antipyretic or pain medication was the same, therefore was included in the column header.

=2008
n

n = Number of participants with the specified reaction.

(%)
Placebo
Dose 1
N=1989
n (%)
COMIRNATY
Dose 2
N=1860
n (%)
Placebo
Dose 2
N=1833
n (%)
Notes: Reactions and use of antipyretic or pain medication were collected in the electronic diary (e-diary) from Day 1 to Day 7 after each dose.
The only Grade 4 solicited systemic reaction reported in participants 56 years of age and older was fatigue.
Fever
  ≥38.0°C26 (1.3)8 (0.4)219 (11.8)4 (0.2)
  ≥38.0°C to 38.4°C23 (1.1)3 (0.2)158 (8.5)2 (0.1)
  >38.4°C to 38.9°C2 (0.1)3 (0.2)54 (2.9)1 (0.1)
  >38.9°C to 40.0°C1 (0.0)2 (0.1)7 (0.4)1 (0.1)
  >40.0°C0000
Fatigue

Mild: does not interfere with activity; Moderate: some interference with activity; Severe: prevents daily activity; Grade 4 reactions were defined in the clinical study protocol as emergency room visit or hospitalization for severe fatigue, severe headache, severe chills, severe muscle pain, or severe joint pain.

  Any677 (33.7)447 (22.5)949 (51.0)306 (16.7)
    Mild415 (20.7)281 (14.1)391 (21.0)183 (10.0)
    Moderate259 (12.9)163 (8.2)497 (26.7)121 (6.6)
    Severe3 (0.1)3 (0.2)60 (3.2)2 (0.1)
    Grade 4001 (0.1)0
Headache
  Any503 (25.0)363 (18.3)733 (39.4)259 (14.1)
    Mild381 (19.0)267 (13.4)464 (24.9)189 (10.3)
    Moderate120 (6.0)93 (4.7)256 (13.8)65 (3.5)
    Severe2 (0.1)3 (0.2)13 (0.7)5 (0.3)
Chills
  Any130 (6.5)69 (3.5)435 (23.4)57 (3.1)
    Mild102 (5.1)49 (2.5)229 (12.3)45 (2.5)
    Moderate28 (1.4)19 (1.0)185 (9.9)12 (0.7)
    Severe01 (0.1)21 (1.1)0
Vomiting

Mild: 1 to 2 times in 24 hours; Moderate: >2 times in 24 hours; Severe: requires intravenous hydration; Grade 4 emergency visit or hospitalization for severe vomiting.

  Any10 (0.5)9 (0.5)13 (0.7)5 (0.3)
    Mild9 (0.4)9 (0.5)10 (0.5)5 (0.3)
    Moderate1 (0.0)01 (0.1)0
    Severe002 (0.1)0
Diarrhea

Mild: 2 to 3 loose stools in 24 hours; Moderate: 4 to 5 loose stools in 24 hours; Severe: 6 or more loose stools in 24 hours; Grade 4: emergency room or hospitalization for severe diarrhea.

  Any168 (8.4)130 (6.5)152 (8.2)102 (5.6)
    Mild137 (6.8)109 (5.5)125 (6.7)76 (4.1)
    Moderate27 (1.3)20 (1.0)25 (1.3)22 (1.2)
    Severe4 (0.2)1 (0.1)2 (0.1)4 (0.2)
New or worsened muscle pain
  Any274 (13.6)165 (8.3)537 (28.9)99 (5.4)
    Mild183 (9.1)111 (5.6)229 (12.3)65 (3.5)
    Moderate90 (4.5)51 (2.6)288 (15.5)33 (1.8)
    Severe1 (0.0)3 (0.2)20 (1.1)1 (0.1)
New or worsened joint pain
  Any175 (8.7)124 (6.2)353 (19.0)72 (3.9)
    Mild119 (5.9)78 (3.9)183 (9.8)44 (2.4)
    Moderate53 (2.6)45 (2.3)161 (8.7)27 (1.5)
    Severe3 (0.1)1 (0.1)9 (0.5)1 (0.1)
Use of antipyretic or pain medication

Severity was not collected for use of antipyretic or pain medication.

382 (19.0)224 (11.3)688 (37.0)170 (9.3)

In participants with chronic, stable HIV infection the frequencies of solicited local and systemic adverse reactions were similar to or lower than those observed for all participants 16 years of age and older.

Unsolicited Adverse Events

Overall, 11,253 (51.1%) participants in the COMIRNATY group and 11,316 (51.4%) participants in the placebo group had follow-up time between ≥4 months to <6 months after Dose 2 in the blinded placebo-controlled follow-up period with an additional 1,778 (8.1%) and 1,304 (5.9%) with ≥6 months of blinded follow-up time in the COMIRNATY and placebo groups, respectively.

A total of 12,006 (54.5%) participants originally randomized to COMIRNATY had ≥6 months total (blinded and unblinded) follow-up after Dose 2.

In an analysis of all unsolicited adverse events reported following any dose, through 1 month after Dose 2, in participants 16 years of age and older (N=43,847; 21,926 COMIRNATY group vs. 21,921 placebo group), those assessed as adverse reactions not already captured by solicited local and systemic reactions were nausea (274 vs. 87), malaise (130 vs. 22), lymphadenopathy (83 vs. 7), asthenia (76 vs. 25), decreased appetite (39 vs. 9), hyperhidrosis (31 vs. 9), lethargy (25 vs. 6), and night sweats (17 vs. 3).

In analyses of all unsolicited adverse events in Study 2 from Dose 1 up to the participant unblinding date, 58.2% of study participants had at least 4 months of follow-up after Dose 2. Among participants 16 through 55 years of age who received at least 1 dose of study vaccine, 12,995 of whom received COMIRNATY and 13,026 of whom received placebo, unsolicited adverse events were reported by 4,396 (33.8%) participants in the COMIRNATY group and 2,136 (16.4%) participants in the placebo group. In a similar analysis in participants 56 years of age and older that included 8,931 COMIRNATY recipients and 8,895 placebo recipients, unsolicited adverse events were reported by 2,551 (28.6%) participants in the COMIRNATY group and 1,432 (16.1%) participants in the placebo group. Among participants with confirmed stable HIV infection that included 100 COMIRNATY recipients and 100 placebo recipients, unsolicited adverse events were reported by 29 (29%) participants in the COMIRNATY group and 15 (15%) participants in the placebo group. The higher frequency of reported unsolicited adverse events among COMIRNATY recipients compared to placebo recipients was primarily attributed to events that are consistent with adverse reactions solicited among participants in the reactogenicity subset (Table 3 and Table 4).

Throughout the placebo-controlled safety follow-up period, Bell's palsy (facial paralysis) was reported by 4 participants in the COMIRNATY group and 2 participants in the placebo group. Onset of facial paralysis was Day 37 after Dose 1 (participant did not receive Dose 2) and Days 3, 9, and 48 after Dose 2. In the placebo group the onset of facial paralysis was Day 32 and Day 102. Currently available information is insufficient to determine a causal relationship with the vaccine. In the analysis of blinded, placebo-controlled follow-up, there were no other notable patterns or numerical imbalances between treatment groups for specific categories of non-serious adverse events (including other neurologic or neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of non-serious adverse events that would suggest a causal relationship to COMIRNATY.

Serious Adverse Events

In Study 2, among participants 16 through 55 years of age who had received at least 1 dose of vaccine or placebo (COMIRNATY =12,995; placebo = 13,026), serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 103 (0.8%) COMIRNATY recipients and 117 (0.9%) placebo recipients. In a similar analysis, in participants 56 years of age and older (COMIRNATY = 8,931; placebo = 8,895), serious adverse events were reported by 165 (1.8%) COMIRNATY recipients and 151 (1.7%) placebo recipients who received at least 1 dose of COMIRNATY or placebo, respectively. In these analyses, 58.2% of study participants had at least 4 months of follow-up after Dose 2. Among participants with confirmed stable HIV infection serious adverse events from Dose 1 up to the participant unblinding date in ongoing follow-up were reported by 2 (2%) COMIRNATY recipients and 2 (2%) placebo recipients.

In the analysis of blinded, placebo-controlled follow-up, there were no notable patterns between treatment groups for specific categories of serious adverse events (including neurologic, neuro-inflammatory, and thrombotic events) that would suggest a causal relationship to COMIRNATY. In the analysis of unblinded follow-up, there were no notable patterns of specific categories of serious adverse events that would suggest a causal relationship to COMIRNATY.

Risk Summary

All pregnancies have a risk of birth defect, loss, or other adverse outcomes. In the US general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Available data on COMIRNATY administered to pregnant women are insufficient to inform vaccine-associated risks in pregnancy.

A developmental toxicity study has been performed in female rats administered the equivalent of a single human dose of COMIRNATY on 4 occasions; twice prior to mating and twice during gestation. These studies revealed no evidence of harm to the fetus due to the vaccine (see Animal Data).

Data

Animal Data

In a developmental toxicity study, 0.06 mL of a vaccine formulation containing the same quantity of nucleoside-modified messenger ribonucleic acid (mRNA) (30 mcg) and other ingredients included in a single human dose of COMIRNATY was administered to female rats by the intramuscular route on 4 occasions: 21 and 14 days prior to mating, and on gestation days 9 and 20. No vaccine-related adverse effects on female fertility, fetal development, or postnatal development were reported in the study.

Risk Summary

It is not known whether COMIRNATY is excreted in human milk. Data are not available to assess the effects of COMIRNATY on the breastfed infant or on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for COMIRNATY and any potential adverse effects on the breastfed child from COMIRNATY or from the underlying maternal condition. For preventive vaccines, the underlying maternal condition is susceptibility to disease prevented by the vaccine.

Efficacy in Participants 16 Years of Age and Older

Study 2 is an ongoing, multicenter, multinational, randomized, placebo-controlled, observer-blind, dose-finding, vaccine candidate–selection, and efficacy study in participants 12 years of age and older. Randomization was stratified by age: 12 through 15 years of age, 16 through 55 years of age, or 56 years of age and older, with a minimum of 40% of participants in the ≥56-year stratum. The study excluded participants who were immunocompromised and those who had previous clinical or microbiological diagnosis of COVID-19. Participants with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease during the 6 weeks before enrollment, were included as were participants with known stable infection with HIV, hepatitis C virus (HCV), or hepatitis B virus (HBV).

In Study 2, based on data accrued through March 13, 2021, approximately 44,000 participants 16 years of age and older were randomized equally and received 2 doses of COMIRNATY or placebo. Participants are planned to be followed for up to 24 months, for assessments of safety and efficacy against COVID-19.

Overall, among the total participants who received COMIRNATY or placebo, 51.4% or 50.3% were male and 48.6% or 49.7% were female, 79.1% or 79.2% were 16 through 64 years of age, 20.9% or 20.8% were 65 years of age and older, 81.9% or 82.1% were White, 9.5% or 9.6% were Black or African American, 1.0% or 0.9% were American Indian or Alaska Native, 4.4% or 4.3% were Asian, 0.3% or 0.2% Native Hawaiian or other Pacific Islander, 25.6% or 25.4% were Hispanic/Latino, 73.9% or 74.1% were non-Hispanic/Latino, 0.5% or 0.5% did not report ethnicity, 46.0% or 45.7% had comorbidities [participants who have 1 or more comorbidities that increase the risk of severe COVID-19 disease: defined as subjects who had at least 1 of the Charlson comorbidity index category or body mass index (BMI) ≥30 kg/m2], respectively. The mean age at vaccination was 49.8 or 49.7 years and median age was 51.0 or 51.0 in participants who received COMIRNATY or placebo, respectively.

Efficacy Against COVID-19

The population for the analysis of the protocol pre-specified primary efficacy endpoint included 36,621 participants 12 years of age and older (18,242 in the COMIRNATY group and 18,379 in the placebo group) who did not have evidence of prior infection with SARS-CoV-2 through 7 days after the second dose. The population in the protocol pre-specified primary efficacy analysis included all participants 12 years of age and older who had been enrolled from July 27, 2020, and followed for the development of COVID-19 through November 14, 2020. Participants 18 through 55 years of age and 56 years of age and older began enrollment from July 27, 2020, 16 through 17 years of age began enrollment from September 16, 2020, and 12 through 15 years of age began enrollment from October 15, 2020.

For participants without evidence of SARS-CoV-2 infection prior to 7 days after Dose 2, vaccine efficacy against confirmed COVID-19 occurring at least 7 days after Dose 2 was 95.0% (95% credible interval: 90.3, 97.6), which met the pre-specified success criterion. The case split was 8 COVID-19 cases in the COMIRNATY group compared to 162 COVID-19 cases in the placebo group.

The population for the updated vaccine efficacy analysis included participants 16 years of age and older who had been enrolled from July 27, 2020, and followed for the development of COVID-19 during blinded placebo-controlled follow-up through March 13, 2021, representing up to 6 months of follow-up after Dose 2. There were 12,796 (60.8%) participants in the COMIRNATY group and 12,449 (58.7%) in the placebo group followed for ≥4 months after Dose 2 in the blinded placebo-controlled follow-up period.

SARS-CoV-2 variants of concern identified from COVID-19 cases in this study include B.1.1.7 (Alpha) and B.1.351 (Beta). Representation of identified variants among cases in vaccine versus placebo recipients did not suggest decreased vaccine effectiveness against these variants.

The updated vaccine efficacy information is presented in Table 5.

Table 5: Vaccine Efficacy – First COVID-19 Occurrence From 7 Days After Dose 2, by Age Subgroup – Participants 16 Years of Age and Older Without Evidence of Infection and Participants With or Without Evidence of Infection Prior to 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population During the Placebo-Controlled Follow-up Period
Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).
First COVID-19 occurrence from 7 days after Dose 2 in participants without evidence of prior SARS-CoV-2 infection

Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

SubgroupCOMIRNATY
N

N = Number of participants in the specified group.

=19,993
Cases
n1

n1 = Number of participants meeting the endpoint definition.


Surveillance Time

Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

(n2

n2 = Number of participants at risk for the endpoint.

)
Placebo
N=20,118
Cases
n1
Surveillance Time (n2)
Vaccine Efficacy %
(95% CI

Two-sided confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted to the surveillance time.

)
All participants77
6.092 (19,711)
833
5.857 (19,741)
91.1
(88.8, 93.1)
  16 through 64 years70
4.859 (15,519)
709
4.654 (15,515)
90.5
(87.9, 92.7)
  65 years and older7
1.233 (4192)
124
1.202 (4226)
94.5
(88.3, 97.8)
First COVID-19 occurrence from 7 days after Dose 2 in participants with or without evidence of prior SARS-CoV-2 infection
SubgroupCOMIRNATY
N=21,047
Cases
n1
Surveillance Time (n2)
Placebo
N=21,210
Cases
n1
Surveillance Time (n2)
Vaccine Efficacy %
(95% CI)
All participants81
6.340 (20,533)
854
6.110 (20,595)
90.9
(88.5, 92.8)
  16 through 64 years74
5.073 (16,218)
726
4.879 (16,269)
90.2
(87.5, 92.4)
  65 years and older7
1.267 (4315)
128
1.232 (4326)
94.7
(88.7, 97.9)

Subgroup analyses of vaccine efficacy (although limited by small numbers of cases in some subgroups) did not suggest meaningful differences in efficacy across genders, ethnic groups, geographies, or for participants with obesity or medical comorbidities associated with high risk of severe COVID-19.

Efficacy Against Severe COVID-19

Efficacy analyses of secondary efficacy endpoints supported benefit of COMIRNATY in preventing severe COVID-19. Vaccine efficacy against severe COVID-19 is presented only for participants with or without prior SARS-CoV-2 infection (Table 6) as the COVID-19 case counts in participants without prior SARS-CoV-2 infection were the same as those in participants with or without prior SARS-CoV-2 infection in both the COMIRNATY and placebo groups.

Table 6: Vaccine Efficacy – First Severe COVID-19 Occurrence in Participants 16 Years of Age and Older With or Without

Participants who had no evidence of past SARS-CoV-2 infection (i.e., N-binding antibody [serum] negative at Visit 1 and SARS-CoV-2 not detected by NAAT [nasal swab] at Visits 1 and 2), and had negative NAAT (nasal swab) at any unscheduled visit prior to 7 days after Dose 2 were included in the analysis.

Prior SARS-CoV-2 Infection Based on Protocol

Severe illness from COVID-19 is defined in the protocol as confirmed COVID-19 and presence of at least 1 of the following:

  • Clinical signs at rest indicative of severe systemic illness (respiratory rate ≥30 breaths per minute, heart rate ≥125 beats per minute, saturation of oxygen ≤93% on room air at sea level, or ratio of arterial oxygen partial pressure to fractional inspired oxygen <300 mm Hg);
  • Respiratory failure [defined as needing high-flow oxygen, noninvasive ventilation, mechanical ventilation or extracorporeal membrane oxygenation (ECMO)];
  • Evidence of shock (systolic blood pressure <90 mm Hg, diastolic blood pressure <60 mm Hg, or requiring vasopressors);
  • Significant acute renal, hepatic, or neurologic dysfunction;
  • Admission to an Intensive Care Unit;
  • Death.
  • or Centers for Disease Control and Prevention (CDC)

    Severe illness from COVID-19 as defined by CDC is confirmed COVID-19 and presence of at least 1 of the following:

    • Hospitalization;
    • Admission to the Intensive Care Unit;
    • Intubation or mechanical ventilation;
    • Death.
    • Definition From 7 Days After Dose 2 – Evaluable Efficacy (7 Days) Population During the Placebo-Controlled Follow-up
Note: Confirmed cases were determined by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) and at least 1 symptom consistent with COVID-19 (symptoms included: fever; new or increased cough; new or increased shortness of breath; chills; new or increased muscle pain; new loss of taste or smell; sore throat; diarrhea; vomiting).
Vaccine Efficacy – First Severe COVID-19 Occurrence
COMIRNATY
Cases
n1

n1 = Number of participants meeting the endpoint definition.


Surveillance Time

Total surveillance time in 1000 person-years for the given endpoint across all participants within each group at risk for the endpoint. Time period for COVID-19 case accrual is from 7 days after Dose 2 to the end of the surveillance period.

(n2

n2 = Number of participants at risk for the endpoint.

)
Placebo
Cases
n1
Surveillance Time (n2)
Vaccine Efficacy %
(95% CI

Two-side confidence interval (CI) for vaccine efficacy is derived based on the Clopper and Pearson method adjusted to the surveillance time.

)
7 days after Dose 21
6.353 (20,540)
21
6.237 (20,629)
95.3
(70.9, 99.9)
Vaccine Efficacy – First Severe COVID-19 Occurrence Based on CDC Definition
COMIRNATY
Cases
n1
Surveillance Time (n2)
Placebo
Cases
n1
Surveillance Time (n2)
Vaccine Efficacy %
(95% CI)
7 days after Dose 20
6.345 (20,513)
31
6.225 (20,593)
100
(87.6, 100.0)

Vial Storage Prior to Use

Cartons of COMIRNATY multiple dose vials with gray caps and labels with gray borders will arrive frozen at ultra-cold conditions in thermal containers with dry ice.

Once received, frozen vials may be immediately transferred to the refrigerator [2°C to 8°C (35°F to 46°F)], thawed and stored for up to 10 weeks. The 10-week refrigerated expiry date should be recorded on the carton at the time of transfer. A carton of 10 vials may take up to 6 hours to thaw at this temperature.

Alternatively, frozen vials may be stored in an ultra-low temperature freezer at -90°C to -60°C (-130°F to -76°F). Do not store vials at -25°C to -15°C (-13°F to 5°F). Once vials are thawed, they should not be refrozen.

If cartons of COMIRNATY multiple dose vials with gray caps and labels with gray borders are received at 2°C to 8°C, they should be stored at 2°C to 8°C. Check that the carton has been updated to reflect the 10-week refrigerated expiry date.

Regardless of storage condition, the vaccine should not be used after the expiration date printed on the vial and cartons.

Vial Storage During Use

If not previously thawed at 2°C to 8°C (35°F to 46°F), allow vials to thaw at room temperature [up to 25°C (77°F)] for 30 minutes.

COMIRNATY multiple dose vials with gray caps and labels with gray borders may be stored at room temperature [8°C to 25°C (46°F to 77°F)] for a total of 12 hours prior to the first puncture. After first puncture, the vial should be held between 2°C to 25°C (35°F to 77°F). Vials should be discarded 12 hours after first puncture.

DO NOT DILUTE PRIOR TO USE.

Transportation of Vials

If local redistribution is needed, vials may be transported at -90°C to -60°C (-130°F to -76°F), or at 2°C to 8°C (35°F to 46°F).

Manufactured for
BioNTech Manufacturing GmbH
An der Goldgrube 12
55131 Mainz, Germany

Manufactured by
Pfizer Inc., New York, NY 10017

LAB-1490-1.0

US Govt. License No. 2229


6.2 Postmarketing Experience



The following adverse reactions have been identified during postmarketing use of COMIRNATY, including under Emergency Use Authorization. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to vaccine exposure.

Cardiac Disorders: myocarditis, pericarditis
Gastrointestinal Disorders: diarrhea, vomiting
Immune System Disorders: severe allergic reactions, including anaphylaxis, and other hypersensitivity reactions (e.g., rash, pruritus, urticaria, angioedema)
Musculoskeletal and Connective Tissue Disorders: pain in extremity (arm)


8.1 Pregnancy



There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to COMIRNATY during pregnancy. Women who are vaccinated with COMIRNATY during pregnancy are encouraged to enroll in the registry by visiting https://mothertobaby.org/ongoing-study/covid19-vaccines/.


8.4 Pediatric Use



Safety and effectiveness of COMIRNATY in individuals 16 through 17 years of age is based on safety and effectiveness data in this age group and in adults [see Adverse Reactions (6) and Clinical Studies (14.1)].

The safety and effectiveness of COMIRNATY in individuals younger than 16 years of age have not been established.


8.5 Geriatric Use



Of the total number of COMIRNATY recipients in Study 2 as of March 13, 2021 (N = 22,026), 20.7% (n = 4,552) were 65 years of age and older and 4.2% (n = 925) were 75 years of age and older [see Clinical Studies (14.1)]. No overall differences in safety or effectiveness were observed between these recipients and younger recipients.


11 Description



COMIRNATY (COVID-19 Vaccine, mRNA) is a sterile suspension for injection for intramuscular use. COMIRNATY is supplied as a frozen suspension in multiple dose vials with gray caps and labels with gray borders. Each 0.3 mL dose of COMIRNATY supplied in multiple dose vials with gray caps and labels with gray borders contains 30 mcg of a nucleoside-modified messenger RNA (mRNA) encoding the viral spike (S) glycoprotein of SARS-CoV-2.

Each 0.3 mL dose of the COMIRNATY supplied in multiple dose vials with gray caps and labels with gray borders also includes the following ingredients: lipids (0.43 mg ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), 0.05 mg 2-(polyethylene glycol 2000)-N,N-ditetradecylacetamide, 0.09 mg 1,2-distearoyl-sn-glycero-3-phosphocholine, and 0.19 mg cholesterol), 0.06 mg tromethamine, 0.4 mg tromethamine hydrochloride, and 31 mg sucrose.

COMIRNATY does not contain preservative.

The vial stoppers are not made with natural rubber latex.


12.1 Mechanism Of Action



The nucleoside-modified mRNA in COMIRNATY is formulated in lipid particles, which enable delivery of the mRNA into host cells to allow expression of the SARS-CoV-2 S antigen. The vaccine elicits an immune response to the S antigen, which protects against COVID-19.


13.1 Carcinogenesis, Mutagenesis, Impairment Of Fertility



COMIRNATY has not been evaluated for the potential to cause carcinogenicity, genotoxicity, or impairment of male fertility. In a developmental toxicity study in rats with COMIRNATY there were no vaccine-related effects on female fertility [see Use in Specific Populations (8.1)].


16 How Supplied/Storage And Handling



COMIRNATY Suspension for Intramuscular Injection, multiple dose vials with gray caps and labels with gray borders are supplied in a carton containing 10 multiple dose vials (NDC 0069-2025-10) or 25 multiple dose vials (NDC 0069-2025-25).

One vial contains 6 doses of 0.3 mL.


Storage And Handling



During storage, minimize exposure to room light, and avoid exposure to direct sunlight and ultraviolet light.

Do not refreeze thawed vials.


17 Patient Counseling Information



Inform vaccine recipient of the potential benefits and risks of vaccination with COMIRNATY.

Inform vaccine recipient of the importance of completing the 2 dose vaccination series.

There is a pregnancy exposure registry for COMIRNATY. Encourage individuals exposed to COMIRNATY around the time of conception or during pregnancy to register by visiting https://mothertobaby.org/ongoing-study/covid19-vaccines/.

Advise vaccine recipient to report any adverse events to their healthcare provider or to the Vaccine Adverse Event Reporting System at 1-800-822-7967 and www.vaers.hhs.gov.

This product's labeling may have been updated. For the most recent prescribing information, please visit https://dailymed.nlm.nih.gov/dailymed/.


Principal Display Panel - 0.3 Ml Vial Label



COVID-19 Vaccine, mRNA
COMIRNATY®

Rx only

DO NOT DILUTE

Vial contains 6 doses of 0.3 mL

For intramuscular use. Contains no preservative.
Discard 12 hours after first use when stored at
2 to 25°C (35 to 77°F).
First use date/time:

US License No. 2229
BioNTech Manufacturing GmbH & Pfizer Inc.


Principal Display Panel - 10 Vial Carton



NDC 0069-2025-10

COVID-19 Vaccine, mRNA
COMIRNATY®

Suspension for Injection, for Intramuscular Use

DO NOT DILUTE

10 Multiple Dose Vials

Each vial contains 6 doses of 0.3 mL

BIONTECH
Pfizer
Rx only


Principal Display Panel - 25 Vial Carton



NDC 0069-2025-25

COVID-19 Vaccine, mRNA
COMIRNATY®

Suspension for Injection, for Intramuscular Use

DO NOT DILUTE

25 Multiple Dose Vials

Each vial contains 6 doses of 0.3 mL

BIONTECH
Pfizer
Rx only


* Please review the disclaimer below.